65 years of the double helix: genetics informs precision practice in the diagnosis and management of pheochromocytoma

HP Neumann, WF Young, T Krauss… - Endocrine-Related …, 2018 - erc.bioscientifica.com
Although the authors of the present review have contributed to genetic discoveries in the
field of pheochromocytoma research, we can legitimately ask whether these advances have …

Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and …

I Janssen, EM Blanchet, K Adams, CC Chen… - Clinical Cancer …, 2015 - AACR
Purpose: Patients with succinate dehydrogenase subunit B (SDHB) mutation–related
pheochromocytoma/paraganglioma (PHEO/PGL) are at a higher risk for metastatic disease …

68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI

I Janssen, CC Chen, D Taieb, NJ Patronas… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent
studies have already shown excellent results in the localization of sympathetic succinate …

Endocrine hypertension

W Young - Endocrine Abstracts, 2011 - endocrine-abstracts.org
Objective: To review the first reported cases of successfully treated pheochromocytoma and
primary aldosteronism and document the diagnostic and therapeutic advances that have …

Increased SSTR2A and SSTR3 expression in succinate dehydrogenase–deficient pheochromocytomas and paragangliomas

MS Elston, GY Meyer-Rochow, HM Conaglen… - Human pathology, 2015 - Elsevier
Many neuroendocrine tumors, including pheochromocytomas (PCs) and paragangliomas
(PGLs), express one or more somatostatin receptors (SSTR1-5). A number of studies have …

Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies

A Angelousi, GK Dimitriadis, G Zografos… - Endocrine-Related …, 2017 - erc.bioscientifica.com
Tumourigenesis is a relatively common event in endocrine tissues. Currently, specific
guidelines have been developed for common malignant endocrine tumours, which also …

[HTML][HTML] Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial

V Nasca, N Prinzi, J Coppa, M Prisciandaro… - European Journal of …, 2024 - Elsevier
Abstract Background Metastatic Pheochromocytomas and paragangliomas (PPGLs) are rare
neuroendocrine tumors characterized by high morbidity and limited systemic treatment …

Neurosurgical causes of pulsatile tinnitus: contemporary update

GM Pingree, C Fleming, J Reavey-Cantwell… - …, 2022 - journals.lww.com
Traditionally in the domain of the otolaryngologist, pulsatile tinnitus (PT) has become
increasingly relevant to neurosurgeons. PT may prove to be a harbinger of life-threatening …

Metastatic pheochromocytomas and paragangliomas: where are we?

N Prinzi, F Corti, M Torchio, M Niger… - Tumori …, 2022 - journals.sagepub.com
Pheochromocytomas and paragangliomas (PPGLs) can metastasize in approximately 15–
20% of cases. This review discusses the available evidence on the biology and treatment of …

Secondary hypertension: An update on the diagnosis and localisation of a pheochromocytoma or paraganglioma

N Siddiqui, R Daya, F Seedat, S Bulbulia… - South African Family …, 2021 - ajol.info
Most cases of hypertension are because of essential hypertension, however 5%–15% of
cases can be a result of a secondary cause. In this article, we focus on the endocrine causes …